AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer.

Frontiers in Oncology
Kun LiuZhi Shi

Abstract

Colorectal cancer is a common malignancy with the third highest incidence and second highest mortality rate among all cancers in the world. Chemotherapy resistance in colorectal cancer is an essential factor leading to the high mortality rate. The ATP-binding cassette (ABC) superfamily G member 2 (ABCG2) confers multidrug resistance (MDR) to a range of chemotherapeutic agents by decreasing their intracellular content. The development of novel ABCG2 inhibitors has emerged as a tractable strategy to circumvent drug resistance. In this study, an ABCG2-knockout colorectal cancer cell line was established to assist inhibitor screening. Additionally, we found that ataxia-telangiectasia mutated (ATM) kinase inhibitor AZ32 could sensitize ABCG2-overexpressing colorectal cancer cells to ABCG2 substrate chemotherapeutic drugs mitoxantrone and doxorubicin by retaining them inside cells. Western blot assay showed that AZ32 did not alter the expression of ABCG2. Moreover, molecule docking analysis predicted that AZ32 stably located in the transmembrane domain of ABCG2. In conclusion, our result demonstrated that AZ32 could potently reverse ABCG2-mediated MDR in colorectal cancer.

References

May 18, 2004·Laboratory Investigation; a Journal of Technical Methods and Pathology·Sylvia AustTheresia Thalhammer
Jul 2, 2005·Cancer Letters·Patricia A FetschSusan E Bates
Feb 27, 2007·Cancer Metastasis Reviews·Robert W RobeySusan E Bates
Dec 9, 2008·Biochemical Pharmacology·Zhi ShiZhe-Sheng Chen
Dec 4, 2009·Recent Patents on Anti-cancer Drug Discovery·Anne KendallNick Maisey
Mar 16, 2011·Cancer Research·Zhi ShiZhe-Sheng Chen
Jan 24, 2012·Recent Patents on Anti-cancer Drug Discovery·Anselmo PapaSilverio Tomao
Feb 27, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Verónica MiguelAna I Álvarez
Sep 23, 2014·The AAPS Journal·Qingcheng Mao, Jashvant D Unadkat
Jul 8, 2015·The Journal of Pharmacology and Experimental Therapeutics·Lora D WeidnerMatthew D Hall
Nov 21, 2015·Anti-cancer Agents in Medicinal Chemistry·Anna Lisa IorioIacopo Sardi
Jan 12, 2016·Therapeutic Advances in Medical Oncology·William A HammondKabir Mody
Jul 3, 2018·Biochemical and Biophysical Research Communications·Wenji ZhangZhi Shi
Nov 6, 2018·Cancer Letters·Yun-Kai ZhangZhe-Sheng Chen
Mar 7, 2020·Biochemical Pharmacology·Daniella KovacsicsBalázs Sarkadi
Mar 17, 2020·Frontiers in Oncology·Jingqiu WangZhe-Sheng Chen
May 10, 2020·Nature Communications·Benjamin J Orlando, Maofu Liao

❮ Previous
Next ❯

Software Mentioned

AutoDock Vina
PyMOL

Related Concepts

Related Feeds

Ataxia telangiectasia

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.